Pharma — Februar 2022
-
Novo/CEO: Har forbedret intern fyldekapacitet for Wegovy
https://www.proinvestor.com/investornyt/774829/novo-ceo-har-forbedret-intern-fyldekapacitet-for-wegovy -
Novo OVERBLIK Q4: Stærk prognose opvejer skuffende drift
https://www.proinvestor.com/investornyt/774945/novo-overblik-q4-staerk-prognose-opvejer-skuffende-drift -
Novo/CFO: Ser stabil driftsmargin i de kommende år
https://www.proinvestor.com/investornyt/774972/novo-cfo-ser-stabil-driftsmargin-i-de-kommende-ar -
Novo/CEO: 2025-mål for fedmeforretning er klart inden for rækkevidde
https://www.proinvestor.com/investornyt/775006/novo-ceo-2025-mal-for-fedmeforretning-er-klart-inden-for-raekkevidde -
Novo/CEO: Læren af Wegovy-problemer kan være større lagre
https://www.proinvestor.com/investornyt/775043/novo-ceo-laeren-af-wegovy-problemer-kan-vaere-storre-lagre -
Novo/SHB: Kursmål løftes til 710 kr. fra 650 kr. - NY
https://www.proinvestor.com/investornyt/775614/novo-shb-kursmal-loftes-til-710-kr-fra-650-kr-ny -
Novo Nordisk/Jyske Bank: Anbefaling hæves til "køb" fra "hold"
https://www.proinvestor.com/investornyt/775629/novo-nordisk-jyske-bank-anbefaling-haeves-til-kob-fra-hold -
Novo Nordisk/DNB: Kursmål hæves til 780 kr. fra 740 kr.
https://www.proinvestor.com/investornyt/775645/novo-nordisk-dnb-kursmal-haeves-til-780-kr-fra-740-kr -
Novo-konkurrenten Eli Lilly slår salgsforventningerne
https://www.proinvestor.com/investornyt/775734/novo-konkurrenten-eli-lilly-slar-salgsforventningerne -
Denne ugekommentar dedikerer Helge Larsen til biotech, nærmere bestemt den nedtur, sektoren har oplevet og stadig oplever. Han kigger bl.a. ned i mulige årsager som rentestigninger, sektorrotation - men også over på markedet i USA med NBI-indekset og mekanismerne her. https://www.proinvestor.com/boards/100739/Ugekommentaren-Nedturen-i-biotech
-
Sanofi Q4 Profit Rises; Sees 2022 Business EPS Growth To Be Low Double-digit At CERhttps://www.proinvestor.com/investornyt/776461/sanofi-q4-profit-rises-sees-2022-business-eps-growth-to-be-low-double-digit-at-cer
-
Novo Nordisk: Topledelse sælger ud efter tildelelse af aktier https://proinvestor.com/investornyt/776726/novo-nordisk-topledelse-saelger-ud-efter-tildelelse-af-aktier
-
Sanofi : FDA Approves Enjaymo, First Treatment For Use In Patients With Cold Agglutinin Disease https://www.proinvestor.com/investornyt/777139/sanofi-fda-approves-enjaymo-first-treatment-for-use-in-patients-with-cold-agglutinin-disease
-
ALK-Abelló OVERBLIK Q4: Tabletsalget overgår forventningerne https://proinvestor.com/investornyt/777902/alk-abello-overblik-q4-tabletsalget-overgar-forventningerne
-
ALK/CEO: Leverer rekordresultater trods udfordringer med corona - NY https://proinvestor.com/investornyt/777913/alk-ceo-leverer-rekordresultater-trods-udfordringer-med-corona-ny
-
ALK/Sydbank: Har stærk vækst ikke mindst i tabletsalget https://proinvestor.com/investornyt/777918/alk-sydbank-har-staerk-vaekst-ikke-mindst-i-tabletsalget
-
Lundbeck laver ny aktiestruktur - deler op i A- og B-aktier - NY https://www.proinvestor.com/investornyt/778641/lundbeck-laver-ny-aktiestruktur-deler-op-i-a-og-b-aktier-ny
-
Lundbeck Q4: Nøgleprodukterne skuffer https://www.proinvestor.com/investornyt/778646/lundbeck-q4-nogleprodukterne-skuffer
-
Lundbeck Q4: Gevaldig skuffelse over hele linjen - NY https://www.proinvestor.com/investornyt/778654/lundbeck-q4-gevaldig-skuffelse-over-hele-linjen-ny
-
Lundbeck/SVB: Kursmål sænkes til 175 kr. fra 200 kr. https://proinvestor.com/investornyt/779372/lundbeck-svb-kursmal-saenkes-til-175-kr-fra-200-kr
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind